← All trials
NCT07067463
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2025
- Primary completion
- Jun 30, 2030
- Completion date
- Jul 31, 2030
- First posted
- Jul 16, 2025
- Last posted
- Jul 16, 2025
- Enrollment
- 705
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Beijing InnoCare Pharma Tech Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.